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Quinci Romero1, Pär-Ola Bendahl1, Mårten Fernö1, Dorthe Grabau3 and Signe Borgquist1,2*Abstract
Background: Ki67 is currently the proliferation biomarker of choice, with both prognostic and predictive value in
breast cancer. A lack of consensus regarding Ki67 use in pre-analytical, analytical and post-analytical practice may
hinder its formal acceptance in the clinical setting.
Methods: One hundred breast cancer samples were stained for Ki67. A standard estimation of Ki67 using fixed
denominators of 200, 400 and 1 000 counted tumor cells was performed, and a cut-off at 20% was applied, Ki67static.
A novel stepwise counting strategy for Ki67 estimation, Ki67scs, was developed based on rejection regions derived
from exact two-sided binomial confidence intervals for proportions. Ki67scs was defined by the following parameters:
the cut-off (20%), minimum (50) and maximum (400) number of tumor cells to count, increment (10) and overall
significance level of the test procedure (0.05). Results from Ki67scs were compared to results from the Ki67static
estimation with fixed denominators.
Results: For Ki67scs, the median number of tumor cells needed to determine Ki67 status was 100; the average,
175. Among 38 highly proliferative samples, the average Ki67scs fraction was 45%. For these samples, the fraction
decreased from 39% to 37% to 35% with static counting of 200, 400 and 1 000 cells, respectively. The largest
absolute difference between the estimation methods was 23% (42% (Ki67scs) vs. 19% (Ki67static)) and resulted in
an altered sample classification. Among the 82 unequivocal samples, 74 samples received the same classification
using both Ki67scs and Ki67static. Of the eight disparate samples, seven were classified highly proliferative by
Ki67static when 200 cells were counted; whereas all eight cases were classified as low proliferative when 1 000
cells were counted.
Conclusions: Ki67 estimation using fixed denominators may be inadequate, particularly for tumors
demonstrating extensive heterogeneity. We propose a time saving stepwise counting strategy, which
acknowledges small highly proliferative hot spots.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.
eu/vs/3588156111195336
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Identification of appropriate patients for adjuvant breast
cancer therapies is a current challenge for medical oncolo-
gists. Optimal clinical decision making is based on both
prognostic and predictive tumor markers [1]. Tumor pro-
liferation is a cornerstone of cancer progression and is
therefore a tantalizing tumor marker [2-4]. Although the
mitotic index is the most established form of proliferation
assessment, it has limitations because the number of* Correspondence: signe.borgquist@med.lu.se
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unless otherwise stated.mitoses per area unit is not linearly related to the rate of
proliferation [5]. Cell-cycle-associated biomarkers, such as
cyclin D1, cyclin E, and p21, have been considered as
prognostic factors [6]. However, the net result of cell cyc-
ling is cell proliferation, and therefore immunohistochem-
ical (IHC) analysis of Ki67 using the MIB-1 antibody has
emerged as the marker of choice with both prognostic
and treatment predictive value in breast cancer [7,8].
Ki67 is a nuclear non-histone protein first identified by
Gerdes et al. in the early 1980’s at the University of Kiel,
Germany. Ki67 was found to be universally expressed
among proliferating cells and absent in quiescent cells,
making it ripe for evaluation as a tumor proliferationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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elusive, although it is thought to be involved in ribosomal
RNA synthesis [12,13]. An antibody with applicability in
paraffin-embedded tissue was eventually developed and
named MIB-1 for the Ki67 gene MKI67 [14].
Ki67 has shown both prognostic and predictive value
in breast cancer [7,8]; however, there is an unfortunate
lack of consensus regarding its use, which hinders its full
clinical acceptance [15]. Significant steps have already
been taken to address this issue [16]. Here, we suggest a
novel strategy to optimize tumor cell evaluation that will
hopefully contribute to the ongoing effort to reach an
international consensus on Ki67-based assessment of
proliferation.
Methods
Study design, patient and tumor characteristics
A retrospective cohort of fifty consecutive breast cancer
patients from 2008 and 2009 with both core biopsy and
corresponding surgical samples available were retrieved
from the Department of Pathology, Skåne University
Hospital, Lund, Sweden. The patients received no inter-
vening anti-cancer treatment between the core biopsy
and surgical excision. In total 2x50 = 100 tumor samples
were included in this study. The Ethical Committee at
Lund University approved the study (Dnr 529). Patient
and sample characteristics have been described previ-
ously [17].
Histopathological analyses
Representative parts of the invasive carcinoma were ex-
cised from surgical specimens and inserted into a cas-
sette for formalin fixation. The cold ischemic time prior
to excision was no longer than one hour. The needle
cores were formalin-fixed immediately after extraction;
the fixation times ranged from 24 to 72 hours. All speci-
mens were paraffin-embedded following fixation. The
sections were cut at 4 μm, deparaffinized, and rehy-
drated in graded ethanol. The antigen retrieval was per-
formed in a microwave oven in citrate buffer pH 6 for
20 min. The expression of Ki67 was determined using the
LSAB+, Dako REAL™ Detection Systems (K5001, Dako,
Glostrup, Denmark). The Ki67 antibody (clone MIB-1,
Dako, Glostrup, Denmark) was diluted 1:500 and incu-
bated for 25 min in a TechMate 500 Plus (Dako, Glostrup,
Denmark) and visualized with 3,3′-Diaminobenzidine. This
assay method conforms to the recommendations of the
International Ki67 Breast Cancer Working Group [16].
Ki67 evaluation
First, haematoxylin and eosin (HE) stains were examined
at x2 and x10 magnification to identify cancerous re-
gions within a tissue sample. Second, the MIB-1 stain
for Ki67 was examined at x2 and x10 magnification toidentify hot spots, i.e., areas with an increased number
of Ki67-positive cells within the previously identified
cancerous regions. Finally, using x40 magnification over
the hot spot, 10 cancer cells at a time were evaluated.
Nuclei more brown than blue were scored positive. The
number of Ki67-positive tumor cells from each set of 10
was recorded. The field of magnification was divided
visually into eight “pie slices” that were evaluated from
the center of the field towards the outer edge. When the
entire field of magnification did not include enough can-
cer cells, a new field was chosen, often within the same
hot spot and adjacent to the original field. If no initial
hot spot could be discerned, a new field was chosen at
random. Each core biopsy and surgical sample was eval-
uated by a single observer (QR) with the observer
blinded to the relationships between the samples. Ki67
assessment was performed twice with a month in be-
tween assessments and the observer blinded to previous
results.
Model development and statistical analysis
A novel stepwise counting strategy (Ki67scs) was devel-
oped to assess the Ki67 status as high, low or equivocal.
To evaluate Ki67scs, the present study reutilized samples
derived for pair-wise comparison of Ki67 levels from
stained sections of pre-operative core biopsies and surgi-
cal samples [17]. Hence, the sample size of 100 was not
determined by means of a power calculation. The strat-
egy performance was evaluated using the set of all 100
samples and the sets of fifty core biopsies and fifty surgi-
cal samples separately.
This novel strategy, with rejection regions based on two-
sided exact binomial tests of the null hypothesis that the
probability of Ki67-positivity is equal to a pre-specified
cut-off, c, included the following steps 1–4:
1. A pre-determined minimum number of tumor cells
(nmin) were evaluated.
2. The resulting estimate, i.e., the fraction of Ki67
positive cells, was compared to the rejection
boundaries defined below. If the estimate belonged
to the upper or lower rejection region, the Ki67
status had been determined and evaluation ceased. If
not, the assessment continued with step 3.
3. An additional number of tumor cells, k (the
increment), was evaluated. It is important to choose
k so that the difference between a predetermined
maximum number of tumor cells (nmax) and nmin is
divisible by k.
4. The new cumulative estimate was compared to the
corresponding rejection boundaries. If the null
hypothesis could be rejected, the Ki67-status had
been determined and evaluation ceased. If not, steps
3–4 were repeated until the null hypothesis was
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reached, or until nmax tumor cells had been evaluated.
If a rejection region was not reached after nmax tumor
cells, then the Ki67 status of the sample was regarded
as equivocal.
The stepwise counting strategy for the parameters used
in this study is summarized numerically in Figure 1.
The rejection regions were based on two-sided exact
binomial tests of the null hypothesis that the probabil-
ity of Ki67-positivity is equal to a pre-specified cut-off,
c. The significance level, α0, for each test was chosen
to keep the overall significance level of the test proced-
ure at α. Simulation under the null hypothesis can be
used to determine α0, a value that varies depending of
the other parameters in the model, i.e. α, c, nmin, k,Figure 1 The stepwise counting procedure in tabular form.
Start by counting 50 cells in a hot spot. If 0-2 cells are positive,
declare the sample as Ki67-negative, and if 19-50 cells are positive,
declare as Ki67-positive. If the number of positive cells is in the 3-18
range, count another 10 cells. If the null hypothesis was not rejected
in the first step, the number of positive cells out of 60 will vary
between 3+0 = 3 and 18+10 = 28. The three possible decisions
based on 60, 70, …, 400 cells are listed in the table. The color-coding is
green for low Ki67, red for high Ki67 and yellow for equivocal Ki67 status.and nmax. The set of model parameters used in this
study were: α = 0.05, c = 0.20, nmin = 50, k = 10, and
nmax = 400.
To determine the appropriate significance level α0 of
each test, a large number of random sequences of nmax
‘zeros’ and ‘ones’ were simulated; in these sequences,
each element is ‘zero’ with probability 1-c and ‘one’ with
probability c. Hence, each of the sequences corresponds
to the evaluation (positive or negative) of nmax cells on a
slide with homogeneous Ki67 staining and with prob-
ability c of positivity for each cell. Following the strategy
described above, the simulated sequences were aggre-
gated to cumulative fractions based on the first nmin,
nmin + k, … , nmax-k, nmax cells. Figure 2 shows cumula-
tive estimates from five such simulations under the null
hypothesis for the set of parameter values above. Figure 3
shows 100 simulations including lower and upper rejec-
tion boundaries (red) derived from the binomial distri-
bution. The boundaries correspond to 99.0% two-sided
confidence intervals (CI). To achieve an α of exactly 5%
for the test procedure is impossible due to the discrete
nature of the test, but extensive simulation (1 000 000
sequences) has shown that by choosing α0 = 0.010, ap-
proximately 5% of the simulations will cross at least one
of the boundaries before or at nmax = 400. This means
that on average five of 100 simulations will falsely lead
to the rejection of the null hypothesis. For the specific
set of 100 randomly chosen simulations shown in Figure 3,
five sequences falsely implied a conclusive Ki67 status;
these sequences are highlighted in green. In total, 48 442
of the 1 000 000 simulations led to rejection of the null
hypothesis, indicating that the test for this set of param-
eter values is slightly conservative. The statistics package
Stata version 12.1 (StataCorp LP 2012, College Station,
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Figure 2 Five sequences of cumulative Ki67 fractions simulated
under the null hypothesis of homogeneity and probability 0.20
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Figure 3 One hundred sequences of cumulative Ki67 fractions
simulated under the null hypothesis of homogeneity and
probability 0.20 of a positive cell. The red curves correspond to
the upper and lower rejection boundaries based on 99.0% exact
two-sided binomial confidence intervals. The five sequences that
cross a boundary are highlighted in green, whereas the remaining
95 are shown in black.
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Demonstration of the novel Ki67 stepwise counting
strategy, Ki67scs
The stepwise counting strategy used in this study is sum-
marized graphically in Figure 4. Four samples depicting dis-
tinct Ki67 situations, i.e., heterogeneous and homogenous
distributions for both high and low proliferative samples,
were chosen to illustrate Ki67scs (Figure 5). The samples’
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Figure 4 A graphical presentation of the step-wise procedure
for determination of Ki67 status. The black jagged line
corresponds to the null hypothesis of probability 0.20 of a positive
cell, the cut-off. The dark region covers the counts for which the null
hypothesis cannot be rejected by a two-sided binomial test at the
1.0% significance level. If the estimate falls in this region, another 10
cells are counted and a new test is performed. If 400 cells have been
counted without reaching the upper or lower rejection regions (light
regions), the Ki67 status of the sample is considered equivocal. If the
upper or lower rejection region is reached for a sample, the counting
is stopped, and the Ki67-status determined.intervals, are shown graphically together with the boundar-
ies of the Ki67scs procedure in Figure 5. As long as a sam-
ple’s cumulative number of Ki67 positive cells was inside
the band of point-wise 99.0% confidence intervals (the dark
field), then another 10 cells were evaluated. If, however, the
cumulative number fell outside the confidence intervals
(the light field), then the Ki67 status of the sample was de-
cided and no further tumor cells were evaluated. All four
Ki67 estimates fell outside the confidence intervals, i.e.,
were classifiable as high (≥20%) or low (<20%) proliferative,
before 200 cancer cells were evaluated. Although stopping
when the rejection region is reached for the first time is
recommended, cumulative estimates are shown all the way
up to nmax = 400 tumor cells in Figure 5. Samples A, C and
D remained outside the confidence intervals and main-
tained their proliferation status as high or low even when
400 cancer cells were evaluated. Sample B, however, chan-
ged classification from highly proliferative at 50 cells to
equivocal at 400 cells. Sample B represents highly prolifera-
tive heterogeneous samples, in other words, samples with
isolated hot spots.
Comparison of Ki67scs with static Ki67 counts of 200, 400
and 1 000 tumor cell sets
The Ki67 stepwise counting strategy, Ki67scs, was com-
pared with static counting (Ki67static) of 200, 400 and 1
000 tumor cells. Using Ki67static, whether for 200, 400 or
1 000 tumor cells, all 100 samples were classified irre-
spective of the proximity of the proliferation value to the
cut-off. The number of samples classified as highly pro-
liferative decreased from 50 via 44 to 34 for 200, 400
and 1 000 cells, respectively. Of the 100 samples, 83
maintained their Ki67 status in all three static counting
sets, with 34 samples consistently scoring as highly pro-
liferative and 49 as low proliferative. Of the remaining
17 samples that did not maintain their Ki67 status, the
number classified as highly proliferative using the Ki67scs
method decreased from 17 via 10 to one for 200, 400
and 1 000 cells, respectively using the Ki67static method.
Ki67scs required a median number of 100 and an aver-
age of 175 counted tumor cells to determine Ki67 status
as high, low or equivocal. Thirty-two of the 100 samples
were classified as high or low after the minimum num-
ber of 50 tumor cells was evaluated, three, as low and
29, as highly proliferative. Eighteen of the 100 samples
were classified as equivocal when the rejection region
could not be reached after the maximum number of 400
tumor cells was evaluated. Of the 82 classifiable samples,
38 were highly proliferative and 44 were low prolifera-
tive. For 74 of these 82 classifiable samples, the Ki67 sta-
tus determined using Ki67scs was consistent with the
status determined using static sets of 200, 400 and 1 000
tumor cells. Of the remaining eight disparately classified
samples, seven were highly proliferative according to
Low proliferative hotspotLow proliferative homogenous
High proliferative hotspotHigh proliferative homogenous
DC
BA
Figure 5 Digital pictures at x10 magnification of four breast cancer samples stained for Ki67. A: A highly proliferative and relatively
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Application of the stopping rule
Figure 6 Demonstration of the stepwise counting strategy
used to determine the Ki67 status of the four cases presented
in Figure 3.
Romero et al. Diagnostic Pathology 2014, 9:118 Page 5 of 8
http://www.diagnosticpathology.org/content/9/1/118either Ki67scs or Ki67static of 200 tumor cells. These same
eight samples were all classified as low proliferative for
Ki67static of 1 000 tumor cells.
For the 38 samples classified as highly proliferative by
Ki67scs, the mean Ki67-estimate (range) was 45% (26–94)
compared with 39% (19–81), 37% (19–81), and 35% (16–81)
using Ki67static of 200, 400, and 1 000 tumor cells, respect-
ively. The largest absolute difference between a Ki67scs esti-
mate and a Ki67static estimate based on 200 cells was 23%
((42% (Ki67scs) vs. 19% (Ki67static)). This is more than a fac-
tor two dilution resulting in an altered Ki67 status using a
cut-off at 20%. The cumulative Ki67 percentage for this
sample (sample B in Figure 5 and 6) is shown in Figure 7,
demonstrating the 99% point-wise CI:s from the Ki67scs.
The Ki67 estimate at 50 cells has a CI excluding the cut-off
of 20%, allowing sample classification as highly proliferative.
However, when additional cells outside the initial hot spot
were included in the Ki67 estimate, the value approached
the cut-off, which could no longer be excluded. The sample
status then changed from highly proliferative to equivocal.
Further, Ki67 was evaluated separately for core biopsies and
surgical samples, respectively, showing essentially the same
results irrespective of the sample type (data not shown).
Intraobserver variability
The 100 samples were evaluated twice by the same ob-
server to assess intraobserver variability. For each of the
two assessments, Ki67scs was applied to the sequences ofcumulative number of positive cells based on 10, 20, …,
1000 cells. In total, 78 of the samples were concordantly
classified, 40 as low, 10 as equivocal and 28 as high. All
but four of the remaining 22 samples were deemed
equivocal based on one of the two assessments, 10 in
the first assessment and 8 in the second. For the last
four samples, the algorithm stopped early, after 50 to 70
cells, the second time after having detected a small hot-
spot which was not detected at the first assessment for
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Cumulative Ki67 estimate with 99.0% CI
Figure 7 Cumulative Ki67 estimate based on 50 to 400 tumor
cells in steps of 10 for the sample (a core biopsy) showing the
largest absolute and relative difference between the model-based
estimate and an estimate based on the fixed counting of 200 cells.
The shaded region is a 99.0% point-wise confidence interval
corresponding to the step-wise test procedure.
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Ki67 is the proliferation biomarker of choice in the re-
search setting [15]; however, a lack of consensus regarding
its use in pre-analytical, analytical, and post-analytical
practice may hinder its formal acceptance in clinical prac-
tice [15,16]. Tissue type, warm and cold ischemic time,
fixation medium and fixation time are examples of pre-
analytical variables. Antibody choice, scoring method or
reporting strategy are examples of analytical and post-
analytical variables [16,18,19]. This study focused on the
post-analytical variables, specifically the number of tumor
cells evaluated and the selection of areas within a tumor
section to be used for Ki67 evaluation. The analytical is-
sues were not addressed here as only one antibody and
one staining method was used.
The International Ki67 in Breast Cancer Working
Group recommends scoring a minimum of 500 invasive
tumor cells over at least three representative fields in-
cluding proliferation zones [16]. However, among studies
using Ki67, the number of tumor cells scored varies
widely, ranging from tens of cells on tissue micro array
cores to as many as 3,000, with a clear tendency towards
the evaluation of larger sets of tumor cells [20,21]. Statis-
tically, evaluating large numbers of cells provides smaller
standard errors and therefore more accurate Ki67 esti-
mates. For a homogenous tumor this would be true.
Tumor proliferation, however, is not normally homoge-
nously expressed [22]. Tumor samples show both intra-
and intersample heterogeneity. In our previous study, the
results obtained from large cell sets with narrow CI:s
could provide inaccurate Ki67 values if samples showed
extensive heterogeneity in proliferation [17]. Thus, hetero-
geneous highly proliferative tumors may be classified as
low proliferative due to a dilution effect. These resultssuggested the need to optimize the number of tumor cells
evaluated in a sample-specific manner. If the optimization
could be standardized, then the intrasample heterogeneity
could be accounted for statistically, and hopefully this
would contribute to the ongoing effort to reach an inter-
national consensus on Ki67 assessment. In this study,
adaption of the model did not seem dependent of samples
type as demonstrated in analyses stratified into samples
from core biopsies versus surgical samples in line with ap-
plied theoretical sampling models [23]. The sampling
models discussed by Kayser et al., point towards the im-
portance of differing between random and stratified sam-
pling, the latter requiring information of a detected object
and the spatial features related to [23].
This presentation and initial evaluation of a novel Ki67
scoring methodology performed in a step-wise dynamic
manner, Ki67scs, is based on targeting hotspots and illus-
trated by setting a minimum number of 50 and max-
imum number of 400 cancer cells to be evaluated and
defining a cut-off of 20% for classifying samples as Ki67
high or low. The general practice in Ki67 scoring is
based on a non-dynamic or static methodology; a pre-
defined number of tumor cells are assessed and the frac-
tion of Ki67 positive cells is determined. Thus, the novel
Ki67scs was compared with the standard static counting
using pre-defined numbers of counted tumor cells. Ki67scs
is currently being developed as an open source computer
program designed to enable variation of the pre-set pa-
rameters suggested and used in this study.
Five critical components of Ki67scs are described here.
First, the rationale for targeting hot spots is based on
the assumption that regions of increased proliferation
are biologically active and presumably relevant for prog-
nosis [7,16]. High tumor proliferation as determined by
Ki67 has been repeatedly demonstrated to be a negative
prognostic factor [20,21,24]. In our previous study, we
showed a significant risk of diluting Ki67 estimates in
heterogeneous samples by including less proliferative
areas of the tumor to achieve the pre-defined number of
cells to be counted [17]. Thus, in this study, Ki67 evalu-
ation was restricted to hot spots, when available. Second,
an initial minimum of 50 invasive cells for Ki67 evalu-
ation was set, presuming that a cluster of 50 highly pro-
liferative invasive cells is enough to encourage aggressive
adjuvant treatment when taken together with supple-
mentary clinical and tumor features. We recognize that
this is a subjective judgment and propose that this lower
limit be adjustable within the Ki67scs program. Third, a
maximum of 400 invasive cells for Ki67 evaluation was
set; this number was based on a doubling of the Swedish
clinical practice of evaluating 200 cells. We acknowledge
that The International Ki67 in Breast Cancer Working
Group working group recommends a minimum of 500
cancer cells for Ki67 evaluation. This recommendation,
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gested above but on representative averages and is
dependent on sample type [16]. In this study, we chose
to designate cases requiring more than 400 tumor cells
for classification as equivocal. In clinical practice, these
cases would employ other factors to guide treatment
choice. An exact cut-off, although attractive in theory,
is not considered feasible in practice due to methodo-
logical limitations. Ideally, no fixed upper limit should
exist. Just as the number of tumor cells evaluated needs
to be optimized for each sample based on its individual
heterogeneity, the upper limit should be flexible. Theoret-
ically, homogeneous samples tolerate a higher upper limit,
whereas highly heterogeneous samples may require a
much lower upper limit to avoid dilution. Therefore, the
upper limit was set as an adjustable parameter within the
Ki67scs program. Fourth, a cut-off of 20% was set for clas-
sification of samples as high or low proliferative based on
South-Swedish clinical practice and as discussed in our
previous work [17]. The literature conveys a plethora of
cut-off values, although cut-offs in the 10%–20% range are
most commonly used to dichotomize Ki67 values [20,25].
Deprived of standardization, cut-offs have limited value
outside the studies and centers from which they origi-
nated. Furthermore, cut-offs are context-related, e.g., a
value appropriate for determination of prognosis may not
be relevant for determination of trial eligibility or for use
as a pharmaco-dynamic marker. We suggest the cut-off
value should be adjustable within the Ki67scs program.
Standardization of Ki67 cut-off values for different breast
cancer types and study goals is an important future chal-
lenge. Fifth, the type I error α of the stepwise procedure
was set to 5%. The stepwise procedure will meet this sig-
nificance level for homogenous samples, but it is not clear
what α will be when the assumption of homogeneity is vi-
olated, i.e. for heterogeneous samples. It will most likely
be larger, but the truth regarding the Ki67 status of sam-
ples with small but highly positive hotspots is unknown.
This well-defined and simple stepwise method will pin-
point some samples as positive which would have been
regarded as negative if a large static number of cells had
been counted. Hence the parameter α should be seen ra-
ther as a tuning parameter than a true type I error. The
aim of Ki67scs is to enable cessation of tumor cell evalu-
ation as soon as a reliable classification is achieved to
reduce the risk of a dilution effect. As an initial dem-
onstration of Ki67scs, we analyzed four cases represent-
ing heterogeneous and homogenous Ki67 distributions
for both high and low proliferative samples, as illus-
trated in Figure 4. As shown in Figure 6, all four sam-
ples were classified based on fewer than 150 tumor
cells using Ki67scs, and samples A, C and D maintained
their Ki67scs classification at 200 and 400 cells. Figure 7
shows an example of an isolated hot spot that wasclassified as highly proliferative after counting only 50
cancer cells. As more cells were evaluated, however,
the Ki67 estimate dropped considerably, from 40% to
less than 20% at 200 cells counted. This illustrates how
a dilution effect can alter a classification from high to
low. The challenges regarding a fixed cut-off should be
noted. An exact cut-off, although attractive in theory,
may not be feasible in practice due to methodological
limitations. When a sample’s Ki67 is too close to the
chosen cut-off it should be categorized as equivocal
and other clinic-pathological variables should be taken
into account. This study is the first to report on a novel
method for Ki67 assessment and we recognize that prior
to application in the clinic, additional improvements are
needed, i.e. studies in a larger cohort assessing the prog-
nostic/predictive value of the equivocal grouping evalu-
ated in order to reach for a “gold standard”.
To further test Ki67scs, we compared the results from
the 100 breast cancer samples, 50 core biopsies and 50
surgical samples with static counting of 200, 400 and 1
000 cells. The number of highly proliferative samples
decreased across the 200, 400 and 1 000 sets, suggest-
ing a dilution. Using Ki67scs, the samples were classi-
fied according to a 20% cut-off as Ki67 high, low or
equivocal. Interestingly, the average Ki67 value for the
highly proliferative samples was ten percentage units
lower using Ki67static with 1 000 cells than Ki67scs
(35% vs. 45%). Larger individual variations were noted,
with an absolute maximum decrease of 23% for a sin-
gle sample.
Automated counting procedures have been investi-
gated in previous publications addressing the utility for
Ki67 assessment [26,27]. In the work by Fasanella et al.,
the authors describe discrepancy in Ki67 results between
automated assessment and human evaluation revealing
higher Ki67 values in the latter [27]. Mohammed et al.,
however report excellent agreement between automated
and visual Ki67 labeling index. As a prognostic tool both
methods were useful, however the visual method being
superior [26]. This study has not addressed automated
Ki67 assessment; however the proposed counting model
should have no limitations favoring either human/visual
or automated counting.
The definition of truth as for Ki67 levels is theoret-
ically interesting, and sums up the ongoing inter-
national discussion on Ki67 assessment. The “true”
Ki67 level may theoretically be the level derived from
a certain assessment method that would depict the
most appropriate prognostic or treatment predictive
value. This paper, however, was not designed to solve
this question, and future studies with long-term follow-up
comparing the static and the sequential method, may be
able to narrow down the most optimal assessment
method.
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To summarize, for Ki67 assessment in breast cancer,
static counting of tumor cells may lead to a diluted Ki67
estimate with the risk of misclassifying a sample, par-
ticularly when heterogeneous and highly proliferative
samples are evaluated. The stepwise counting strategy
presented herein may reduce the risk of diluting the
Ki67 estimate. Attempting to optimize the number of in-
vasive cancer cells assessed for each sample allows for
sample heterogeneity and hopefully contributes to the
current consensus discussion regarding Ki67 evaluation.
Future studies are needed to validate our model in an in-
dependent dataset, address the prognostic value of the
suggested Ki67 assessment method, and to test inter-
observer agreement with this novel strategy.
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